Pfizer’s Hympavzi Wins FDA Approval to Treat Hemophilia

Pfizer Inc.’s Hympavzi won US approval to treat hemophilia, a potentially deadly genetic disorder that prevents blood from clotting properly.

The once-weekly injection prevents or reduces the frequency of bleeding episodes that can do long-term damage to patients, Pfizer said in a statement. The drug, the first in a new class of medicines for the condition, costs $795,600 annually, the company said.

Hympavzi is approved for patients aged 12 and older with hemophilia A or B who haven’t developed antibodies to previous treatment, called inhibitors. It may be more convenient for those with hemophilia B, who usually require ...